Published in Mol Ther on October 09, 2007
HCV drug discovery aimed at viral eradication. J Viral Hepat (2009) 1.19
Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev Vaccines (2009) 1.08
Current status and future directions in the management of chronic hepatitis C. Virol J (2012) 0.99
Human dendritic cells and transplant outcome. Transplantation (2008) 0.92
Hepatic enrichment and activation of myeloid dendritic cells during chronic hepatitis C virus infection. Hepatology (2012) 0.91
Distinctive pattern of sequence polymorphism in the NS3 protein of hepatitis C virus type 1b reflects conflicting evolutionary pressures. J Gen Virol (2008) 0.86
Current progress in the development of a prophylactic vaccine for HIV-1. Drug Des Devel Ther (2010) 0.85
Dendritic cell-based immunity and vaccination against hepatitis C virus infection. Immunology (2012) 0.83
Hepatitis C virus modulates human monocyte-derived dendritic cells. J Viral Hepat (2010) 0.81
Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection. Mol Ther Methods Clin Dev (2015) 0.80
Chemokine programming dendritic cell antigen response: part I - select chemokine programming of antigen uptake even after maturation. Immunology (2013) 0.76
Chemokine programming dendritic cell antigen response: part II - programming antigen presentation to T lymphocytes by partially maintaining immature dendritic cell phenotype. Immunology (2013) 0.75
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol (2013) 2.63
A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences. Nucleic Acids Res (2006) 2.38
Molecular basis of xeroderma pigmentosum group C DNA recognition by engineered meganucleases. Nature (2008) 2.37
Efficient targeting of a SCID gene by an engineered single-chain homing endonuclease. Nucleic Acids Res (2009) 2.14
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04
Engineering of large numbers of highly specific homing endonucleases that induce recombination on novel DNA targets. J Mol Biol (2005) 2.04
Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res (2008) 1.92
Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology (2008) 1.87
Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology (2005) 1.75
Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance. Liver Transpl (2013) 1.66
CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol (2003) 1.61
Inhibiting expression of specific genes in mammalian cells with 5' end-mutated U1 small nuclear RNAs targeted to terminal exons of pre-mRNA. Proc Natl Acad Sci U S A (2003) 1.55
Cardiotrophin-1 reduces ischemia/reperfusion injury during liver transplant. J Surg Res (2012) 1.45
Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells. Hepatology (2011) 1.44
Amphiregulin: an early trigger of liver regeneration in mice. Gastroenterology (2005) 1.44
Biliary secretion of S-nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat. Hepatology (2010) 1.41
Up-regulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology (2012) 1.38
The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J Virol (2009) 1.36
Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology (2007) 1.32
Effect of adenovirus-mediated RNA interference on endogenous microRNAs in a mouse model of multidrug resistance protein 2 gene silencing. J Virol (2006) 1.32
The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med (Maywood) (2009) 1.31
Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J Virol (2007) 1.29
Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol (2005) 1.23
Hepatitis C virus envelope components alter localization of hepatocyte tight junction-associated proteins and promote occludin retention in the endoplasmic reticulum. Hepatology (2008) 1.23
Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res (2008) 1.21
The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis. Hepatology (2008) 1.20
Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol (2002) 1.19
Novel role for amphiregulin in protection from liver injury. J Biol Chem (2005) 1.19
Molecular basis of engineered meganuclease targeting of the endogenous human RAG1 locus. Nucleic Acids Res (2010) 1.19
Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol (2005) 1.18
Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol (2010) 1.17
Homing endonucleases: from basics to therapeutic applications. Cell Mol Life Sci (2010) 1.16
Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger. Hepatology (2006) 1.16
Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol Immunother (2010) 1.15
Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res (2006) 1.14
Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res (2006) 1.14
Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol (2004) 1.13
Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy. Am J Transplant (2003) 1.13
Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol (2003) 1.13
Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats. Hepatology (2010) 1.12
Cardiotrophin-1 is a key regulator of glucose and lipid metabolism. Cell Metab (2011) 1.12
Anion exchanger 2 is essential for spermiogenesis in mice. Proc Natl Acad Sci U S A (2003) 1.11
A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. Cytokine (2003) 1.08
The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo. J Immunol (2007) 1.08
De Novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl (2005) 1.07
A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovasc Res (2008) 1.07
Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer. J Hepatol (2007) 1.06
Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. Cancer Res (2011) 1.06
A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism. Cancer Res (2008) 1.05
Gene therapy of cancer with interleukin-12. Curr Pharm Des (2003) 1.04
A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice. J Immunol (2010) 1.03
Development of a liver-specific Tet-on inducible system for AAV vectors and its application in the treatment of liver cancer. Mol Ther (2011) 1.03
Cardiotrophin-1 defends the liver against ischemia-reperfusion injury and mediates the protective effect of ischemic preconditioning. J Exp Med (2006) 1.02
Expression of Wilms' tumor suppressor in the liver with cirrhosis: relation to hepatocyte nuclear factor 4 and hepatocellular function. Hepatology (2003) 1.01
Crystal structure of I-DmoI in complex with its target DNA provides new insights into meganuclease engineering. Proc Natl Acad Sci U S A (2008) 1.01
Structure of the AvrBs3-DNA complex provides new insights into the initial thymine-recognition mechanism. Acta Crystallogr D Biol Crystallogr (2013) 1.01
Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin Cancer Res (2002) 1.01
Identification of peptide inhibitors of transforming growth factor beta 1 using a phage-displayed peptide library. Cytokine (2007) 1.01